This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-23. Anything still debated is marked as such rather than presented as settled.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
=== Solvent affinity === Suspensions of nanoparticles are possible since the interaction of the particle surface with the solvent is strong enough to overcome density differences, which otherwise usually result in a material either sinking or floating in a liquid.
Hochman had previously worked for the Ron DeSantis 2024 presidential campaign but was fired after producing a promotional video for DeSantis that featured fascist imagery, including a sonnenrad, a symbol used by neo-Nazis and white supremacists. In September 2025, Hochman promoted a speech on social media that Schmitt delivered at the National Conservatism Conference, titled "What is an American?". In the speech Schmitt criticized legal immigration, and said that America was not a "universal proposition" open to anyone. He said, "Our people tamed the continent, built a civilization from the wilderness ... We Americans are the sons and daughters of the Christian pilgrims who poured out onto the ocean's shores ... America belongs to us, and only us." Of America's founders, he said: "They fought, they bled, they struggled, they died for us. They built this country for us. America, in all its glory, is their gift to us, handed down across the generations. It belongs to us. It's our birthright, our heritage, our destiny. If America is everything and everyone, then it is nothing and no one at all. But we know that's not true. America is not a 'universal nation.'" The Guardian asked Schmitt's office if Hochman was involved in writing the speech; Schmitt's office did not reply. Ed Kilgore of New York Magazine said Schmitt's speech promoted the idea of America as a "blood and soil homeland"; David Corn called it "implied white supremacy".
=== Molecular biology === In 1954, at the age of 37, Crick completed his PhD thesis: "X-Ray Diffraction: Polypeptides and Proteins" and received his degree. Crick then worked in the laboratory of David Harker at Brooklyn Polytechnic Institute, where he continued to develop his skills in the analysis of X-ray diffraction data for proteins, working primarily on ribonuclease and the mechanisms of protein synthesis. David Harker, the American X-ray crystallographer, was described as "the John Wayne of crystallography" by Vittorio Luzzati, a crystallographer at the Centre for Molecular Genetics in Gif-sur-Yvette near Paris, who had worked with Rosalind Franklin. After the discovery of the double helix model of DNA, Crick's interests quickly turned to the biological implications of the structure. In 1953, Watson and Crick published another article in Nature which stated: "it therefore seems likely that the precise sequence of the bases is the code that carries the genetical information".
Sources: en.wikipedia.org
Like DNA, most biologically active RNAs, including mRNA, tRNA, rRNA, snRNAs, and other non-coding RNAs, contain self-complementary sequences that allow parts of the RNA to fold and pair with itself to form double helices. Analysis of these RNAs has revealed that they are highly structured. Unlike DNA, their structures do not consist of long double helices, but rather collections of short helices packed together into structures akin to proteins. In this fashion, RNAs can achieve chemical catalysis (like enzymes). For instance, determination of the structure of the ribosome—an RNA-protein complex that catalyzes the assembly of proteins—revealed that its active site is composed entirely of RNA.
"Standard weapon grade plutonium requires a 240Pu content of no more than 6.5%." which is 65,000 ppm, and the analogous 238Pu was produced in levels of 0.5% (5,000 ppm) or less). Gun-type fission weapons additionally need low levels (1 ppm range) of light impurities, to keep the neutron generation low. The production of "clean" 233U, low in 232U, requires a few factors: 1) obtaining a relatively pure 232Th source, low in 230Th (which also transmutes to 232U), 2) moderating the incident neutrons to have an energy not higher that 6 MeV (too-high energy neutrons cause the 232Th (n,2n) → 231Th reaction) and 3) removing the thorium sample from neutron flux before the 233U concentration builds up to a too high level, in order to avoid fissioning the 233U itself (which would produce energetic neutrons). The Molten-Salt Reactor Experiment (MSRE) used 233U that contained 222 ppm 232U.
The Georgia Sustainment and Stability Operations Program (GSSOP) was a security assistance program designed to create an increased capability in the Georgian military to support Operation Iraqi Freedom stability missions. Launched in January 2005, GSSOP was also designed to help solidify the progress made during the Georgia Train and Equip Program (GTEP) of 2002–2004 and continue to assist in the implementation of western standards in the Georgian armed forces. The first phase of the program (GSSOP-I) lasted about 18 months and cost approximately $60 million. It ended in October 2006 to be succeeded by GSSOP-II, which lasted until June 2007. The training was conducted, primarily at the Krtsanisi National Training Centre near Tbilisi, by the United States Army Special Forces and United States Marine Corps Forces, Europe. The beneficiaries were the 22nd, 23rd, 31st, 32nd and 33rd Light Infantry Battalions, logistic battalions of the 1st, 2nd, and 3rd Infantry Brigades, the reconnaissance companies of the 2nd and 3rd Infantry Brigades, communication companies of the 2nd and 3rd Brigades, and an independent military police company. On August 31, 2009, the U.S. and Georgia inaugurated the Georgia Deployment Program—International Security Assistance Force (GDP—ISAF) In order to prepare the Georgian units for deployment in Afghanistan as part of the International Security Assistance Force. Originally planned as a two-year engagement, the success of past missions has extended the pairing as the Georgia Deployment Program—Resolute Support Mission (GDP—RSM) into 2020.
== The economic crisis in Germany == Hitler's interest in Czechoslovakia was largely economic. Germany had the second-largest economy in the world, but German agriculture was not capable of feeding the population, and there was also a lack of many raw materials, which had to be imported. The Four-Year Plan that Hitler had launched in September 1936 to have the German economy ready for a "total war" by 1940 had seriously strained the German economy by 1937 as German government was forced to use up its foreign exchange reserves both to feed its own people and to import various raw materials to achieve the ambitious armament goals of the Four Year Plan. Though the Four Year Plan aimed at autarky, there were certain raw materials such as high-grade iron, oil, chrome, nickel, tungsten, and bauxite that Germany did not have and had to be imported. The need to import food and raw materials made Germany into Europe's second largest importer, being exceeded only by Great Britain. Moreover, hundreds of millions of Reichsmarks were spent on immense armament works such as the Reichswerke steel complex, an expensive program to develop synthetic fuel, as well as various costly chemical and metallurgical programs, all of which strained the German economy. The Great Depression was an era beset by trade wars and protectionism, which put further straining on the German export market and ability to generate foreign exchange. Moreover, the Four Year Plan with its aim of autarky led to Germany increasing its tariffs, which led other nations to do likewise in retaliation.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.